Fat digestion is required for suppression of ghrelin and stimulation of peptide YY and pancreatic polypeptide secretion by intraduodenal lipid

2005 ◽  
Vol 289 (6) ◽  
pp. E948-E953 ◽  
Author(s):  
Christine Feinle-Bisset ◽  
Michael Patterson ◽  
Mohammad A. Ghatei ◽  
Stephen R. Bloom ◽  
Michael Horowitz
Keyword(s):  
Pancreatic Polypeptide ◽  
Peptide Yy ◽  
Young Males ◽  
Healthy Humans ◽  
Fat Digestion ◽  
Fat Infusion ◽  
Glucagon Like Peptide 1 ◽  
Induced Changes ◽  
Ghrelin Secretion ◽  
Stimulation Of

Stimulation of cholecystokinin and glucagon-like peptide-1 secretion by fat is mediated by the products of fat digestion. Ghrelin, peptide YY (PYY), and pancreatic polypeptide (PP) appear to play an important role in appetite regulation, and their release is modulated by food ingestion, including fat. It is unknown whether fat digestion is a prerequisite for their suppression (ghrelin) or release (PYY, PP). Moreover, it is not known whether small intestinal exposure to fat is sufficient to suppress ghrelin secretion. Our study aimed to resolve these issues. Sixteen healthy young males received, on two separate occasions, 120-min intraduodenal infusions of a long-chain triglyceride emulsion (2.8 kcal/min) 1) without (condition FAT) or 2) with (FAT-THL) 120 mg of tetrahydrolipstatin (THL, lipase inhibitor), followed by a standard buffet-style meal. Blood samples for ghrelin, PYY, and PP were taken throughout. FAT infusion was associated with a marked, and progressive, suppression of plasma ghrelin from t = 60 min ( P < 0.001) and stimulation of PYY from t = 30 min ( P < 0.01). FAT infusion also stimulated plasma PP (P ≤ 0.01), and the release was immediate. FAT-THL completely abolished the FAT-induced changes in ghrelin, PYY, and PP. In response to the meal, plasma ghrelin was further suppressed, and PYY and PP stimulated, during both FAT and FAT-THL infusions. In conclusion, in healthy humans, 1) the presence of fat in the small intestine suppresses ghrelin secretion, and 2) fat-induced suppression of ghrelin and stimulation of PYY and PP is dependent on fat digestion.

scholarly journals Modulation of Food Intake by Differential TAS2R Stimulation in Rat

Nutrients ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3784
Author(s):  
Carme Grau-Bové ◽  
Alba Miguéns-Gómez ◽  
Carlos González-Quilen ◽  
José-Antonio Fernández-López ◽  
Xavier Remesar ◽  
...  
Keyword(s):  
Food Intake ◽  
Peptide Yy ◽  
Reduce Food Intake ◽  
Intestinal Segments ◽  
Regulate Food Intake ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Specific Stimulation ◽  
Ghrelin Secretion ◽  
Stimulation Of

Metabolic surgery modulates the enterohormone profile, which leads, among other effects, to changes in food intake. Bitter taste receptors (TAS2Rs) have been identified in the gastrointestinal tract and specific stimulation of these has been linked to the control of ghrelin secretion. We hypothesize that optimal stimulation of TAS2Rs could help to modulate enteroendocrine secretions and thus regulate food intake. To determine this, we have assayed the response to specific agonists for hTAS2R5, hTAS2R14 and hTAS2R39 on enteroendocrine secretions from intestinal segments and food intake in rats. We found that hTAS2R5 agonists stimulate glucagon-like peptide 1 (GLP-1) and cholecystokinin (CCK), and reduce food intake. hTAS2R14 agonists induce GLP1, while hTASR39 agonists tend to increase peptide YY (PYY) but fail to reduce food intake. The effect of simultaneously activating several receptors is heterogeneous depending on the relative affinity of the agonists for each receptor. Although detailed mechanisms are not clear, bitter compounds can stimulate differentially enteroendocrine secretions that modulate food intake in rats.

scholarly journals Glycaemic, gastrointestinal, hormonal and appetitive responses to pearl millet or oats porridge breakfasts: a randomised, crossover trial in healthy humans

2019 ◽  
Vol 122 (10) ◽  
pp. 1142-1154
Author(s):  
Jaber Alyami ◽  
Ella Whitehouse ◽  
Gleb E. Yakubov ◽  
Susan E. Pritchard ◽  
Caroline L. Hoad ◽  
...  
Keyword(s):  
Pearl Millet ◽  
Crossover Trial ◽  
Peptide Yy ◽  
Health Benefit ◽  
Gastric Volume ◽  
Time Data ◽  
Insulin Metabolism ◽  
Beneficial Effects ◽  
Healthy Humans ◽  
Glucagon Like Peptide 1

AbstractWhole-grain cereal breakfast consumption has been associated with beneficial effects on glucose and insulin metabolism as well as satiety. Pearl millet is a popular ancient grain variety that can be grown in hot, dry regions. However, little is known about its health effects. The present study investigated the effect of a pearl millet porridge (PMP) compared with a well-known Scottish oats porridge (SOP) on glycaemic, gastrointestinal, hormonal and appetitive responses. In a randomised, two-way crossover trial, twenty-six healthy participants consumed two isoenergetic/isovolumetric PMP or SOP breakfast meals, served with a drink of water. Blood samples for glucose, insulin, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide (GIP), peptide YY, gastric volumes and appetite ratings were collected 2 h postprandially, followed by an ad libitum meal and food intake records for the remainder of the day. The incremental AUC (iAUC2h) for blood glucose was not significantly different between the porridges (P > 0·05). The iAUC2h for gastric volume was larger for PMP compared with SOP (P = 0·045). The iAUC2h for GIP concentration was significantly lower for PMP compared with SOP (P = 0·001). Other hormones and appetite responses were similar between meals. In conclusion, the present study reports, for the first time, data on glycaemic and physiological responses to a pearl millet breakfast, showing that this ancient grain could represent a sustainable alternative with health-promoting characteristics comparable with oats. GIP is an incretin hormone linked to TAG absorption in adipose tissue; therefore, the lower GIP response for PMP may be an added health benefit.

Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans

2012 ◽  
Vol 15 (5) ◽  
pp. 474-477 ◽  
Author(s):  
T. Wu ◽  
M. J. Bound ◽  
S. D. Standfield ◽  
B. Gedulin ◽  
K. L. Jones ◽  
...  
Keyword(s):  
Peptide Yy ◽  
Rectal Administration ◽  
Taurocholic Acid ◽  
Healthy Humans ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Gastrointestinal Satiety Signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide

2004 ◽  
Vol 286 (5) ◽  
pp. G693-G697 ◽  
Author(s):  
Sarah Stanley ◽  
Katie Wynne ◽  
Steve Bloom
Keyword(s):  
Gastrointestinal Tract ◽  
Animal Models ◽  
Eating Behavior ◽  
Pancreatic Polypeptide ◽  
Peptide Yy ◽  
Gastrointestinal Function ◽  
L Cells ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Many peptides are synthesized and released from the gastrointestinal tract and pancreas, including pancreatic polypeptide (PP) and the products of the gastrointestinal L cells, glucagon-like peptide 1 (GLP-1), oxyntomodulin, and peptide YY (PYY). Whereas their roles in regulation of gastrointestinal function have been known for some time, it is now evident that they also influence eating behavior. This review considers the anorectic peptides PYY, PP, GLP-1, and oxyntomodulin, which decrease appetite and promote satiety in both animal models and humans.

scholarly journals Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans

2014 ◽  
Vol 306 (7) ◽  
pp. G622-G630 ◽  
Author(s):  
Rune E. Kuhre ◽  
Fiona M. Gribble ◽  
Bolette Hartmann ◽  
Frank Reimann ◽  
Johanne A. Windeløv ◽  
...  
Keyword(s):  
Peptide Yy ◽  
Hormone Secretion ◽  
Gut Hormones ◽  
Glucagon Secretion ◽  
Healthy Humans ◽  
Murine Cell Line ◽  
Gut Hormone ◽  
Glucagon Like Peptide 1 ◽  
Cell Depolarization ◽  
Gip Release

Nutrients often stimulate gut hormone secretion, but the effects of fructose are incompletely understood. We studied the effects of fructose on a number of gut hormones with particular focus on glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). In healthy humans, fructose intake caused a rise in blood glucose and plasma insulin and GLP-1, albeit to a lower degree than isocaloric glucose. Cholecystokinin secretion was stimulated similarly by both carbohydrates, but neither peptide YY3–36nor glucagon secretion was affected by either treatment. Remarkably, while glucose potently stimulated GIP release, fructose was without effect. Similar patterns were found in the mouse and rat, with both fructose and glucose stimulating GLP-1 secretion, whereas only glucose caused GIP secretion. In GLUTag cells, a murine cell line used as model for L cells, fructose was metabolized and stimulated GLP-1 secretion dose-dependently (EC50= 0.155 mM) by ATP-sensitive potassium channel closure and cell depolarization. Because fructose elicits GLP-1 secretion without simultaneous release of glucagonotropic GIP, the pathways underlying fructose-stimulated GLP-1 release might be useful targets for type 2 diabetes mellitus and obesity drug development.

Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity

2005 ◽  
Vol 289 (3) ◽  
pp. R729-R737 ◽  
Author(s):  
Karine Proulx ◽  
Daniela Cota ◽  
Tamara R. Castañeda ◽  
Matthias H. Tschöp ◽  
David A. D'Alessio ◽  
...  
Keyword(s):  
Food Intake ◽  
Motor Activity ◽  
Peptide Yy ◽  
Metabolic Effects ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Apolipoprotein A ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Induced Changes

Oleoylethanolamide (OEA), a lipid synthesized in the intestine, reduces food intake and stimulates lipolysis through peroxisome proliferator-activated receptor-α. OEA also activates transient receptor potential vanilloid type 1 (TRPV1) in vitro. Because the anorexigenic effect of OEA is associated with delayed feeding onset and reduced locomotion, we examined whether intraperitoneal administration of OEA results in nonspecific behavioral effects that contribute to the anorexia in rats. Moreover, we determined whether circulating levels of other gut hormones are modulated by OEA and whether CCK is involved in OEA-induced anorexia. Our results indicate that OEA reduces food intake without causing a conditioned taste aversion or reducing sodium appetite. It also failed to induce a conditioned place aversion. However, OEA induced changes in posture and reduced spontaneous activity in the open field. This likely underlies the reduced heat expenditure and sodium consumption observed after OEA injection, which disappeared within 1 h. The effects of OEA on motor activity were similar to those of the TRPV1 agonist capsaicin and were also observed with the peroxisome proliferator-activated receptor-α agonist Wy-14643. Plasma levels of ghrelin, peptide YY, glucagon-like peptide 1, and apolipoprotein A-IV were not changed by OEA. Finally, antagonism of CCK-1 receptors did not affect OEA-induced anorexia. These results suggest that OEA suppresses feeding without causing visceral illness and that neither ghrelin, peptide YY, glucagon-like peptide 1, apolipoprotein A-IV, nor CCK plays a critical role in this effect. Despite that OEA-induced anorexia is unlikely to be due to impaired motor activity, our data raise a cautionary note in how specific behavioral and metabolic effects of OEA should be interpreted.

scholarly journals The Effect of Multidisciplinary Lifestyle Intervention on the Pre- and Postprandial Plasma Gut Peptide Concentrations in Children with Obesity

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Rimke C. Vos ◽  
Hanno Pijl ◽  
Jan M. Wit ◽  
Erik W. van Zwet ◽  
Chris van der Bent ◽  
...  
Keyword(s):  
Peptide Yy ◽  
Multidisciplinary Treatment ◽  
Plasma Concentrations ◽  
Area Under The Curve ◽  
Resistance Index ◽  
Gut Hormones ◽  
Obese Children ◽  
Glucagon Like Peptide 1 ◽  
Treatment Of Obesity ◽  
Ghrelin Secretion

Objective. This study aims to evaluate the effect of a multidisciplinary treatment of obesity on plasma concentrations of several gut hormones in fasting condition and in response to a mixed meal in children. Methods. Complete data were available from 36 obese children (age 13.3±2.0 yr). At baseline and after the 3-month multidisciplinary treatment, fasting and postprandial blood samples were taken for glucose, insulin, ghrelin, peptide YY (PYY), and glucagon-like peptide 1 (GLP-1). Results. BMI-SDS was significantly reduced by multidisciplinary treatment (from 4.2±0.7 to 4.0±0.9, P<.01). The intervention significantly increased the area under the curve (AUC) of ghrelin (from 92.3±18.3 to 97.9±18.2 pg/L, P<.01), but no significant changes were found for PYY or GLP-1 concentrations (in fasting or postprandial condition). The insulin resistance index (HOMA-IR) remained unchanged as well. Conclusion. Intensive multidisciplinary treatment induced moderate weight loss and increased ghrelin secretion, but serum PYY and GLP-1 concentrations and insulin sensitivity remained unchanged.

scholarly journals Effects of L-Phenylalanine on Energy Intake and Glycaemia—Impacts on Appetite Perceptions, Gastrointestinal Hormones and Gastric Emptying in Healthy Males

Nutrients ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1788 ◽  
Author(s):  
Penelope C. E. Fitzgerald ◽  
Benoit Manoliu ◽  
Benjamin Herbillon ◽  
Robert E. Steinert ◽  
Michael Horowitz ◽  
...  
Keyword(s):  
Gastric Emptying ◽  
Energy Intake ◽  
Plasma Glucose ◽  
Peptide Yy ◽  
Peak Plasma ◽  
Gastrointestinal Hormones ◽  
Postprandial Blood Glucose ◽  
Double Blind ◽  
Glucagon Like Peptide 1 ◽  
Stimulation Of

In humans, phenylalanine stimulates plasma cholecystokinin (CCK) and pyloric pressures, both of which are important in the regulation of energy intake and gastric emptying. Gastric emptying is a key determinant of postprandial blood glucose. We evaluated the effects of intragastric phenylalanine on appetite perceptions and subsequent energy intake, and the glycaemic response to, and gastric emptying of, a mixed-nutrient drink. The study consisted of two parts, each including 16 healthy, lean males (age: 23 ± 1 years). In each part, participants received on three separate occasions, in randomised, double-blind fashion, 5 g (Phe-5 g) or 10g (‘Phe-10 g) L-phenylalanine, or control, intragastrically, 30 min before a standardised buffet-meal (part A), or a standardised mixed-nutrient drink (part B). In part A, plasma CCK and peptide-YY (PYY), and appetite perceptions, were measured at baseline, after phenylalanine alone, and following the buffet-meal, from which energy intake was assessed. In part B, plasma glucose, glucagon-like peptide-1 (GLP-1), insulin and glucagon were measured at baseline, after phenylalanine alone, and for 2 h following the drink. Gastric emptying of the drink was also measured by 13C-acetate breath-test. Phe-10 g, but not Phe-5 g, stimulated plasma CCK (p = 0.01) and suppressed energy intake (p = 0.012); energy intake was correlated with stimulation of CCK (r = −0.4, p = 0.027), and tended to be associated with stimulation of PYY (r = −0.31, p = 0.082). Both Phe-10 g and Phe-5 g stimulated insulin and glucagon (all p < 0.05), but not GLP-1. Phe-10 g, but not Phe-5 g, reduced overall plasma glucose (p = 0.043) and peak plasma glucose (p = 0.017) in response to the mixed-nutrient drink. Phenylalanine had no effect on gastric emptying of the drink. In conclusion, our observations indicate that the energy intake-suppressant effect of phenylalanine is related to the stimulation of CCK and PYY, while the glucoregulatory effect may be independent of stimulation of plasma GLP-1 or slowing of gastric emptying.

scholarly journals Length and site of the small intestine exposed to fat influences hunger and food intake

2011 ◽  
Vol 106 (10) ◽  
pp. 1609-1615 ◽  
Author(s):  
P. W. Jeroen Maljaars ◽  
Harry P. F. Peters ◽  
Andrea Kodde ◽  
Maartje Geraedts ◽  
Fred J. Troost ◽  
...  
Keyword(s):  
Small Intestine ◽  
Food Intake ◽  
Peptide Yy ◽  
Control Treatment ◽  
Liquid Meal ◽  
Animal Data ◽  
Oral Control ◽  
Fat Infusion ◽  
Glucagon Like Peptide 1 ◽  
Experimental Treatments

The site of intestinal fat delivery affects satiety and may affect food intake in humans. Animal data suggest that the length of the small intestine exposed to fat is also relevant. The aim of the present study was to investigate whether increasing the areas of intestinal fat exposure and the way it is exposed would affect satiety parameters and food intake. In the present single-blind, randomised, cross-over study, fifteen volunteers, each intubated with a naso-ileal tube, received four treatments on consecutive days. The oral control (control treatment) was a liquid meal (LM) containing 6 g fat ingested att = 0 min, with saline infusion att = 30–120 min. Experimental treatments were a fat-free LM att = 0 min, with either 6 g oil delivered sequentially (2 g duodenal,t = 30–60 min; 2 g jejunal,t = 60–90 min; 2 g ileal,t = 90–120 min), simultaneously (2 g each to all sites,t = 30–120 min) or ileal only (6 g ileal,t = 30–120 min). Satiety parameters (hunger and fullness) and cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), peptide YY (PYY) secretion were measured untilt = 180 min, whenad libitumfood intake was assessed. Only the ileum treatment reduced food intake significantly over the control treatment. The ileum and simultaneous treatments significantly reduced hunger compared with the control treatment. Compared with control, no differences were observed for PYY, CCK and GLP-1 with regard to 180 min integrated secretion. Ileal fat infusion had the most pronounced effect on food intake and satiety. Increasing the areas of intestinal fat exposure only affected hunger when fat was delivered simultaneously, not sequentially, to the exposed areas. These results demonstrate that ileal brake activation offers an interesting target for the regulation of ingestive behaviour.

Sign in / Sign up

Export Citation Format

Share Document